6-chloro-9-((2-(trimethylsilyl)ethoxy)methyl)-9H-purin-2-amine | 552315-15-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 6-chloro-9-((2-(trimethylsilyl)ethoxy)methyl)-9H-purin-2-amine
• 英文别名: 6-Chloro-9-((2-(trimethylsilyl)ethoxy)methyl)-9H-purin-2-amine；6-chloro-9-(2-trimethylsilylethoxymethyl)purin-2-amine
• CAS: 552315-15-8
• 化学式: C₁₁H₁₈ClN₅OSi
• 分子量: 299.835
• InChiKey: FVUNVTRGGBOQLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.37
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  78.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-chloro-9-((2-(trimethylsilyl)ethoxy)methyl)-9H-purin-2-amine 在 copper(l) iodide 、 四(三苯基膦)钯 、 四丁基氟化铵 、 碘 、 sodium hydride 、 碳酸氢钠 、 二甲基亚砜 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 N-(2,6-difluorophenyl)-2-(2-fluorophenyl)-7H-purin-6-amine
  参考文献：
  名称：

  N-Phenyl-N-purin-6-yl ureas: The design and synthesis of p38α MAP kinase inhibitors

  摘要：

  The design, synthesis and SAR of a series of 2,6,9-trisubstituted purine inhibitors of p38alpha kinase is reported. Synthetic routes were devised to allow for array synthesis in which all three points of diversity could be facilely explored. The binding of this novel series to p38alpha kinase, which was predicted to have several key interactions in common with SB-203580, was confirmed by X-ray crystallography of 19 (p38 IC50 = 82 nM). (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00048-9
• 作为产物：
  描述：

  2-(三甲基硅烷基)乙氧甲基氯 、 2-氨基-6-氯嘌呤 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以58%的产率得到6-chloro-9-((2-(trimethylsilyl)ethoxy)methyl)-9H-purin-2-amine
  参考文献：
  名称：

  BICYCLIC PIPERAZINE COMPOUNDS

  摘要：

  提供了公式I的双环哌嗪化合物，包括其立体异构体、互变异构体和药学上可接受的盐，用于抑制Btk激酶，并用于治疗由Btk激酶介导的炎症等免疫紊乱。公开了使用公式I化合物进行体外、体内和体内诊断以及治疗哺乳动物细胞中的这类紊乱，或相关的病理条件的方法。

  公开号：

  US20130116262A1

文献信息

• BICYCLIC PIPERAZINE COMPOUNDS
  申请人：Genentech, Inc.

  公开号：US20130116262A1

  公开（公告）日：2013-05-09

  Bicyclic piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  提供了公式I的双环哌嗪化合物，包括其立体异构体、互变异构体和药学上可接受的盐，用于抑制Btk激酶，并用于治疗由Btk激酶介导的炎症等免疫紊乱。公开了使用公式I化合物进行体外、体内和体内诊断以及治疗哺乳动物细胞中的这类紊乱，或相关的病理条件的方法。
• Bicyclic piperazine compounds
  申请人：Genentech, Inc.

  公开号：US08722676B2

  公开（公告）日：2014-05-13

  Bicyclic piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  本发明提供了公式I的双环哌嗪化合物，包括立体异构体、互变异构体和其药学上可接受的盐，用于抑制Btk激酶和治疗由Btk激酶介导的免疫紊乱，如炎症。本发明还揭示了使用公式I的化合物用于哺乳动物细胞中这种紊乱的体外、体内和原位诊断和治疗，或相关的病理状况的方法。
• N-Phenyl-N-purin-6-yl ureas: The design and synthesis of p38α MAP kinase inhibitors
  作者：Zehong Wan、Jeffrey C. Boehm、Michael J. Bower、Shouki Kassis、John C. Lee、Baoguang Zhao、Jerry L. Adams

  DOI：10.1016/s0960-894x(03)00048-9

  日期：2003.3

  The design, synthesis and SAR of a series of 2,6,9-trisubstituted purine inhibitors of p38alpha kinase is reported. Synthetic routes were devised to allow for array synthesis in which all three points of diversity could be facilely explored. The binding of this novel series to p38alpha kinase, which was predicted to have several key interactions in common with SB-203580, was confirmed by X-ray crystallography of 19 (p38 IC50 = 82 nM). (C) 2003 Elsevier Science Ltd. All rights reserved.